Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | angiotensin-converting enzyme family protein | 0.0691 | 1 | 1 |
Onchocerca volvulus | Matrilysin homolog | 0.0164 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | extracellular metallopeptidase | 0.0337 | 0.3285 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0179 | 0.028 | 0.028 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0268 | 0.1987 | 0.5 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0164 | 0 | 0.5 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0268 | 0.1987 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Average change in body weight (functional) | = 0.7 % | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma . | ChEMBL. | 3806580 |
Average change in body weight (functional) | = 0.7 % | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma . | ChEMBL. | 3806580 |
Average change in body weight (functional) | = 5.8 % | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. Average change in body weight from onset to termination of therapy.. | ChEMBL. | 3806580 |
Average change in body weight (functional) | = 5.8 % | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. Average change in body weight from onset to termination of therapy.. | ChEMBL. | 3806580 |
OD (functional) | = 50 mg kg-1 | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. Optimum effective daily dose administered once daily for 6 consecutive days | ChEMBL. | 3806580 |
OD (functional) | = 50 mg kg-1 | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. Optimum effective daily dose administered once daily for 6 consecutive days | ChEMBL. | 3806580 |
OD (functional) | = 150 mg kg-1 | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma, Optimum effective daily dose administered once daily for 6 consecutive days | ChEMBL. | 3806580 |
OD (functional) | = 150 mg kg-1 | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma, Optimum effective daily dose administered once daily for 6 consecutive days | ChEMBL. | 3806580 |
T/C (functional) | = 100 % | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. | ChEMBL. | 3806580 |
T/C (functional) | = 100 % | Compound was evaluated for antineoplastic activity against mice bearing L1210 leukemia. | ChEMBL. | 3806580 |
T/C (functional) | = 112 % | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma . | ChEMBL. | 3806580 |
T/C (functional) | = 112 % | Compound was evaluated for antineoplastic activity against mice bearing B6 melanoma . | ChEMBL. | 3806580 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.